Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Market Cap
465.1M
52 Wk Range
$1.61 - $6.42
Previous Close
$4.47
Open
$4.52
Volume
2,844,320
Day Range
$4.41 - $4.92
Enterprise Value
296.1M
Cash
175.4M
Avg Qtr Burn
-28.75M
Insider Ownership
0.88%
Institutional Own.
75.19%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |